Author/Editor		Drinovec, Jože
Title		Biotehnologija in farmacevtska industrija
Translated title		Biotechnology and pharmaceutical industry
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 66, št. 10
Publication year		1997
Volume		str. 511-2
Language		slo
Abstract		Background. Medical biotechnology is based on DNA technology and its main objective is to extract protein healing agents from microbial and mammalian cells. Research efforts led to registration of at least 29 biotechnological drugs with documented therapeutic effect and acceptable toxicity. Conclusions. Modern biotechnological drugs have the molecular structure identical to that of human organism. The downside is that they are parenteral and expensive. Biotechnological pharmaceutical industry is growing into a very successful and profitable branch with products which complement traditional pharmaceuticals to patient's benefit.
Summary		Izhodišča. Medicinska biotehnologija temelji na tehnologiji DNA in pridobivanju beljakovinskih zdravilnih učinkovin iz mikrobnih celic ali celic sesalcev. Raziskovalna prizadevanja so imela za posledico registracijo vsaj 29 biotehnoloških zdravil z dokazanim terapevtskim učinkom in sprejemljivo toksičnostjo. Zaključki. Sodobna biotehnološka zdravila so kot molekule identična fiziološkim substancam v organizmu. Njihova slabost je izključno parenteralna uporaba in visoka cena. Biotehnološka farmacevtska industrija se razvija kot ekonomsko zelo pomembna panoga, ki za bolnike koristno in uspešno dopolnjuje tradicionalno nefarmacevtske proizvode.
Descriptors		DRUG INDUSTRY BIOTECHNOLOGY ANTIBODIES, MONOCLONAL